
AMA Urges Federal Shield Against AI Liability for Doctors
The American Medical Association (AMA) is calling for federal and state legislation to shield doctors from liability when artificial intelligence (AI) tools they rely upon cause harm to patients. This push comes as the healthcare industry rapidly integrates increasingly sophisticated AI technologies into clinical settings, raising complex legal questions about responsibility and accountability.
According to the AMA's policy statement, physicians should not be held liable for malpractice if an AI product is used as intended but results in patient injury. The organization argues that manufacturers of these tools, along with hospitals and health systems requiring their use, should bear the brunt of any liability instead. This stance reflects a growing concern among medical professionals about the potential legal ramifications of relying on AI-driven decision-making in critical healthcare scenarios.
The AMA's proposal also includes calls for mandatory insurance coverage by AI companies to mitigate financial risks associated with product failures and for these firms to provide transparent information regarding their products' limitations and performance metrics. Such measures are seen as crucial steps toward ensuring that the deployment of AI technologies does not undermine patient safety or compromise medical standards.
As AI systems take on more significant roles in clinical decision-making, including triage assessments and treatment recommendations, there is heightened awareness of potential pitfalls. Legal experts highlight scenarios where AI might misjudge a patient's condition due to incomplete data or outdated information, leading to erroneous decisions that could harm patients. In such cases, the AMA contends that responsibility should lie with those who develop and deploy these systems rather than the physicians using them.
The urgency behind this push is underscored by recent legal challenges involving algorithm-driven medical errors. For instance, a wrongful death lawsuit in Alabama highlighted issues surrounding the use of AI screening tools for detecting heart abnormalities. In this case, the software developer was not held liable because the licensing agreement stipulated that final clinical decisions remained with healthcare providers.
Professor Martin Hilbert from the University of California, Davis, emphasizes that courts are increasingly recognizing the need to hold AI manufacturers accountable when their systems cause harm. However, determining liability can be complicated by factors such as shared responsibility among multiple parties involved in developing an AI system and proving fault within opaque algorithmic models.
The Food and Drug Administration (FDA) is currently evaluating whether new regulatory frameworks are necessary for overseeing AI-enabled medical devices. While the FDA regulates software classified as a medical device, it does not oversee all forms of AI used in healthcare. This distinction highlights the broader challenge of establishing comprehensive oversight across the entire spectrum of AI applications in medicine.
Hospitals and health systems generally support placing accountability on developers and vendors to monitor AI system performance due to the inherent complexity and opacity of many algorithms. However, industry groups like AdvaMed are advocating for continued use of existing FDA approaches while cautioning against overly burdensome post-market monitoring that may not be justified by a product's actual risk profile.
The AMA's initiative aims to address situations where the use of AI systems is mandatory, ensuring that healthcare providers can confidently rely on these tools without fear of legal repercussions. As AI continues to transform medical practice, such measures are critical for balancing innovation with patient safety and professional accountability.
Latest News





